180 Life Sciences Reports Positive Results from Study on New CBD Formulation with Improved Oral Absorption

PALO ALTO, Calif., July 30, 2024 -- 180 Life Sciences Corp. (NASDAQ: ATNF) recently revealed the primary outcomes of a clinical pharmacology study that examined the absorption of cannabidiol (CBD) in a solid pill form. This research was carried out in collaboration with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and Prof. Elyad Davidson from Hadassah Hospital. The study aimed to compare the pharmacokinetic profiles of two solid CBD formulations with Epidiolex, an FDA-approved liquid CBD medication used for epilepsy.

Epidiolex is typically administered as a liquid solution containing CBD dissolved in ethanol and sesame seed oil, with added flavoring agents. In the study, 12 volunteers participated in a crossover randomized trial where they received all three formulations. The key finding was that one of the solid forms of CBD was absorbed more quickly and reached higher maximum levels compared to Epidiolex, while both solid forms showed good tolerance among participants.

CBD, known for its non-psychoactive properties, has shown potential benefits in treating inflammation and pain. However, its oral absorption, especially in liquid form, tends to be inconsistent and variable. This challenge prompted Prof. Domb and his team to develop ProNanoLipospheres (PNL), which are tiny droplets designed to enhance absorption from the gastrointestinal tract into the bloodstream.

The clinical trial conducted at Hadassah Hospital on 12 adult males demonstrated that one of the PNL-based capsules outperformed Epidiolex in terms of absorption speed and peak levels. The other PNL formulation was found to be statistically equivalent to Epidiolex in these metrics. This suggests that PNL capsules could be a more effective and predictable method for delivering CBD compared to the current liquid forms.

The success of these solid formulations could significantly impact the clinical testing of CBD for various conditions, including pain, PTSD, and head trauma. Testing a solid, orally administered CBD capsule could facilitate easier and more reliable dosing, potentially broadening its clinical applications.

Prof. Avi Domb highlighted the potential commercial and medical benefits of this new solid formulation. He suggested that, upon further clinical validation, this approach could offer healthcare providers a more precise and high-uptake method for prescribing CBD, thus overcoming the limitations associated with liquid formulations. This shift could lead to greater acceptance among both doctors and patients.

Although the full results of the study are pending, the promising initial outcomes indicate a potential advancement in CBD delivery methods. These findings are expected to be published in a scientific journal in the future. 180 Life Sciences does not foresee any immediate impact of this study on its financial results for the year ending December 31, 2024.

In summary, 180 Life Sciences Corp. has made significant strides in the development of solid CBD formulations, which could revolutionize the delivery and effectiveness of CBD for various therapeutic uses. This innovation opens up new possibilities for treating chronic pain, inflammation, and other conditions with a more reliable and efficient method. The ongoing research and anticipated publications will further elucidate the benefits and potential of these novel formulations.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!